Answers are grounded in this paper and cite their sources.
Checkpoint inhibitors, compared with docetaxel, are associated with significantly prolong overall survival in second-line therapy in NSCLC. The finding of no overall survival benefit for patients with EGFR mutant tumors suggests that checkpoint inhibitors should be considered only after other effective therapies have been exhausted. The findings of this meta-analysis could also assist in the design and interpretation of future trials and in economic analyses.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: